UNSPSC 51322604: Tizoprolic acid

This classification denotes an anti-lipidemic agent with the molecular formula C7H9NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VGT0G37N5M, chemically known as 5-thiazolecarboxylic acid, 2-propyl- but generally known as tizoprolic acid, which bears US NIH Compound Identifier 65773. European Medicines Agency schedules Tizoprolic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11131MIG.

UNSPSC 51322604 Tizoprolic acid is a Commodity code covering pharmaceutical active pharmaceutical ingredients and finished medications sourced by state and local health agencies, fire rescue services, and pharmacy benefit programs. State and local governments buy under this code primarily as finished pharmaceutical products—injectable medications, OTC pharmaceuticals, and active ingredients supplied through direct manufacturer contracts, cooperative purchasing agreements, and competitive sealed bidding processes. Issuing bodies span state health and human services departments, municipal fire rescue services, and multistate cooperative purchasing alliances. The scope includes compliance requirements for cGMP certification, Drug Supply Chain Security Act (DSCSA) adherence, FDA registration, Safety Data Sheets (SDSs) conformance to OSHA standards, and accessibility documentation per WCAG 2.2 and Section 508 federal standards when applicable.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 (due April 8, 2026) for Advanced Life Support Medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000 and a Small Local Business Enterprise (SLBE) sheltered market designation offering a 5 percent bid discount. The Minnesota Department of Administration issued RFP S1070000015802 (due March 26, 2026) through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and participating jurisdictions, requiring distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with award effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 (response deadline April 3, 2026) to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program targeting direct contracting outside existing PBM, GPO, and wholesaler arrangements, indicating early-stage state-level procurement planning in pharmaceutical supply chain restructuring.